HI
CVKD icon

Harbour Investments’s Cadrenal Therapeutics CVKD Stock Holding History

Harbour Investments’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$512 – 4805
2026
Q1 		$512 Hold
100
– – ﹤0.01% 4250
2025
Q4 		$678 Hold
100
– – ﹤0.01% 3509
2025
Q3 		$1.38K Hold
100
– – ﹤0.01% 3358
2025
Q2 		$1.21K Buy
+100
New +$1.49K ﹤0.01% 3245

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Harbour Investments's CVKD Position: Q2 2026 in Review

Harbour Investments sold out of Cadrenal Therapeutics (CVKD) in Q2 2026, closing a stake of 100 shares — an estimated $512 sold.

Harbour Investments first reported a position in CVKD in Q2 2025 and held it in 4 quarters. The position peaked at $1.38K in Q3 2025. 20 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • Harbour Investments reported no remaining Cadrenal Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Harbour Investments sold 100 Cadrenal Therapeutics shares in Q2 2026, an estimated $512.
  • Harbour Investments first reported a position in Cadrenal Therapeutics in Q2 2025 and held it in 4 quarters.
  • Harbour Investments's Cadrenal Therapeutics position peaked at $1.38K in Q3 2025.
  • 20 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.